Article Text

Download PDFPDF
Acute coronary syndromes
The vulnerable atherosclerotic plaque: in vivo identification and potential therapeutic avenues
  1. Philip D Adamson,
  2. Marc R Dweck,
  3. David E Newby
  1. Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
  1. Correspondence to Dr Philip D Adamson, Centre for Cardiovascular Science, University of Edinburgh, SU305 Chancellor's Building, 47 Little France Crescent, Edinburgh EH16 4TJ, UK; philip.adamson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Learning objectives

  • Describe the concept of the vulnerable plaque and features associated with vulnerability.

  • Discuss techniques that may be useful for the identification of potentially vulnerable plaques.

  • Suggest how these imaging strategies may inform development of plaque stabilisation therapies.


Worldwide more than 17 million people die every year from cardiovascular disease (CVD) with this number projected to increase to over 23 million by 2030.1 Within Europe, CVD results in four million deaths annually, accounting for 47% of all-cause mortality. Between them, heart attacks and strokes are responsible for around 80% of this mortality.2 The vast majority of acute ischaemic vascular events occur in relation to an underlying atherosclerotic plaque. Plaque rupture is the dominant initiating event, responsible for 60–70% of acute coronary syndromes (ACS), while plaque erosion is responsible for most of the remainder.3 ,4 Irrespective of the mechanism, the consequence is exposure of a thrombogenic substrate to circulating blood. This in turn triggers platelet aggregation and the coagulation cascade which compromises vascular blood flow resulting in downstream end-organ ischaemia and infarction. These events occur abruptly and often without warning. Despite intensive therapies, they recur in as many as 25% of patients.

Until recently, the high-risk plaque has only been identified by retrospective analysis, predominantly from pathological examination of autopsy specimens. This has limited our ability to appreciate the dynamic nature of plaque vulnerability and rupture, and has placed a heavy reliance on invasive angiography to describe the anatomical luminal stenosis severity rather than plaque biology. Prospective identification of plaque rupture events has suggested that the majority of culprit lesions is non-flow limiting, and often overlooked by angiographic and traditional functional investigations. Novel imaging techniques now have the potential to identify the pathological structures and processes associated with plaque rupture. This in turn has raised hopes for strategies …

View Full Text


  • Contributors PDA wrote the draft. MRD and DEN made substantial contributions in revising the final work.

  • Funding PDA is supported by the New Zealand Heart Foundation. MRD and DEN are supported by the British Heart Foundation (FS/14/78/31020 and CH/09/002) and the Wellcome Trust (WT103782AIA).

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles